TY - JOUR
T1 - Thromboembolic Risk After Atriopulmonary, Lateral Tunnel, and Extracardiac Conduit Fontan Surgery
AU - Alliance for Adult Research in Congenital Cardiology (AARCC)
AU - Deshaies, Catherine
AU - Hamilton, Robert M.
AU - Shohoudi, Azadeh
AU - Trottier, H.
AU - Poirier, N.
AU - Aboulhosn, J.
AU - Broberg, Craig S.
AU - Cohen, S.
AU - Cook, Stephen
AU - Dore, A.
AU - Fernandes, Susan M.
AU - Fournier, Anne
AU - Kay, Joseph
AU - Mondésert, Blandine
AU - Mongeon, François Pierre
AU - Opotowsky, Alexander R.
AU - Proietti, Anna
AU - Ting, Jennifer
AU - Zaidi, Ali
AU - Khairy, Paul
N1 - Funding Information:
The authors thank Marie-Claude Villeneuve, MSc (Montreal Health Innovations Coordinating Center); Aynun Naher, MBBS, MS (Oregon Health and Science University); William R. Davidson, Jr. MD, John J. Kelleman, MD, Elizabeth E. Adams, DO, and Dena Jefferson RN, BSN, CCRC (Hershey Medical Center); Morgan Hindes (Children's Hospital of Pittsburgh); Ryan Williams and Gwen Derk (University of California, Los Angeles); Michael G. Earing, MD, Jonathan W. Cramer, MD, and Emily Reinhardt, RN (Medical College of Wisconsin); and Meena Fatah (Hospital for Sick Children, Toronto). Dr. Deshaies was supported by a grant from the Dalhousie University Department of Surgery Research Office and Dr. Khairy by a chair in electrophysiology and congenital heart disease. The study was funded by an investigator-initiated unrestricted grant from Boehringer Ingelheim. The sponsor had no role in study design, data collection, analysis, interpretation or publication of the findings. Dr. Mongeon has served on the advisory board on pulmonary hypertension medications in patients with congenital heart disease for Actelion. Dr. Opotowsky has received research grants from Roche Diagnostics and Actelion; has served on the Data and Safety Monitoring Board for Acetlion; and has served as a consultant for Novartis. P.K. Shah, MD, served as Guest Editor-in-Chief for this paper.
Publisher Copyright:
© 2019 American College of Cardiology Foundation
PY - 2019/8/27
Y1 - 2019/8/27
N2 - Background: Thromboembolic events contribute greatly to morbidity and mortality following Fontan surgery for univentricular hearts. Objectives: This study sought to evaluate the effect of type of Fontan surgery on thromboembolic risk. Methods: A North American multicenter retrospective cohort study enrolled 522 patients with Fontan palliation consisting of an atriopulmonary connection (APC) (21.4%), lateral tunnel (LT) (41.8%), or extracardiac conduit (EC) (36.8%). Thromboembolic complications and new-onset atrial arrhythmia were reviewed and classified by a blinded adjudicating committee. Thromboembolic risk across surgical techniques was assessed by multivariable competing-risk survival regression. Results: Over a median follow-up of 11.6 years, 10- and 20-year freedom from Fontan conversion, transplantation, or death was 94.7% and 78.9%, respectively. New-onset atrial arrhythmias occurred in 4.4, 1.2, and 1.0 cases per 100 person-years with APC, LT, and EC, respectively. APC was associated with a 2.82-fold higher risk of developing atrial arrhythmias (p < 0.001), with no difference between LT and EC (p = 0.95). A total of 71 thromboembolic events, 32 systemic and 39 venous, occurred in 12.8% of subjects, for an overall incidence of 1.1%/year. In multivariable analyses, EC was independently associated with a lower risk of systemic (hazard ratio [HR]: 0.20 vs. LT; 95% confidence interval [CI]: 0.04 to 0.97) and combined (HR: 0.34 vs. LT; 95% CI: 0.13 to 0.91) thromboembolic events. A lower incidence of combined thromboembolic events was also observed with antiplatelet agents (HR: 0.54; 95% CI: 0.32 to 0.92) but not anticoagulation (p = 0.53). Conclusions: The EC Fontan was independently associated with a lower thromboembolic risk after controlling for time-varying effects of atrial arrhythmias and thromboprophylaxis.
AB - Background: Thromboembolic events contribute greatly to morbidity and mortality following Fontan surgery for univentricular hearts. Objectives: This study sought to evaluate the effect of type of Fontan surgery on thromboembolic risk. Methods: A North American multicenter retrospective cohort study enrolled 522 patients with Fontan palliation consisting of an atriopulmonary connection (APC) (21.4%), lateral tunnel (LT) (41.8%), or extracardiac conduit (EC) (36.8%). Thromboembolic complications and new-onset atrial arrhythmia were reviewed and classified by a blinded adjudicating committee. Thromboembolic risk across surgical techniques was assessed by multivariable competing-risk survival regression. Results: Over a median follow-up of 11.6 years, 10- and 20-year freedom from Fontan conversion, transplantation, or death was 94.7% and 78.9%, respectively. New-onset atrial arrhythmias occurred in 4.4, 1.2, and 1.0 cases per 100 person-years with APC, LT, and EC, respectively. APC was associated with a 2.82-fold higher risk of developing atrial arrhythmias (p < 0.001), with no difference between LT and EC (p = 0.95). A total of 71 thromboembolic events, 32 systemic and 39 venous, occurred in 12.8% of subjects, for an overall incidence of 1.1%/year. In multivariable analyses, EC was independently associated with a lower risk of systemic (hazard ratio [HR]: 0.20 vs. LT; 95% confidence interval [CI]: 0.04 to 0.97) and combined (HR: 0.34 vs. LT; 95% CI: 0.13 to 0.91) thromboembolic events. A lower incidence of combined thromboembolic events was also observed with antiplatelet agents (HR: 0.54; 95% CI: 0.32 to 0.92) but not anticoagulation (p = 0.53). Conclusions: The EC Fontan was independently associated with a lower thromboembolic risk after controlling for time-varying effects of atrial arrhythmias and thromboprophylaxis.
KW - Fontan procedure
KW - atrial arrhythmia
KW - single ventricle
KW - thromboembolism
KW - thromboprophylaxis univentricular heart
UR - http://www.scopus.com/inward/record.url?scp=85070517891&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070517891&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2019.06.051
DO - 10.1016/j.jacc.2019.06.051
M3 - Article
C2 - 31439217
AN - SCOPUS:85070517891
SN - 0735-1097
VL - 74
SP - 1071
EP - 1081
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 8
ER -